The MAPT gene, which encodes the tau protein, has been explored as a potential biomarker for distinguishing tauopathies, such as PSP and CBD, from other neurodegenerative diseases, including PD and multiple system atrophy (MSA). Here, MAPT is linked to supranuclear palsy, progressive, 1.